New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
16:50 EDTFPRXFive Prime reports Q2 EPS (46c), consensus (27c)
Reports Q2 revenue $4.98M, consensus $6.65M. Net loss was primarily due to the advancement of FPA144 towards a Q4 IND submission and public company-related expenses, partially offset by an increase in collaboration revenue.
News For FPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:00 EDTFPRXBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
November 17, 2014
16:54 EDTFPRXFive Prime initiates dosing of RA patients in FPA008 Phase 1 clinical trial
Five Prime Therapeutics discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis, or RA, patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor, or CSF1R. FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use